Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hammann

Showing results (141-150 of 526) with videos related to

Pageof 53
Sort By:
Clinical Pharmacology and Therapeutics|March 12, 2010
Prediction of adverse drug reactions using decision tree modelingF Hammann, H Gutmann, N Vogt, et al.
Virchows Archiv. A, Pathological Anatomy and Histopathology|January 1, 1991
Growth characteristics and metastatic potential of seven intestinal carcinoma lines serially passaged in syngeneic ratsM S Martin, F Martin, M F Michel, et al.
European Journal of Radiology|May 3, 2014
Volumetric quantification of the effect of aging and hormone replacement therapy on breast composition from digital mammogramsJ S Hammann-Kloss, U Bick, E Fallenberg, et al.
Genome Biology|August 23, 2001
Gene trapping identifies transiently induced survival genes during programmed cell deathF Wempe, J Y Yang, J Hammann, et al.
RNA (New York, N.Y.)|March 29, 2012
The ubiquitous hammerhead ribozymeChristian Hammann, Andrej Luptak, Jonathan Perreault, et al.
The Journal of Biological Chemistry|March 13, 1999
Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugsO Micheau, E Solary, A Hammann, et al.
Fortschritte Der Medizin|April 28, 1977
[The rectal carcinoma. Characteristics of the tumor and its position within the framework of colonic neoplasms]H J Hammann, M Eckert, H D Fux, et al.
RNA (New York, N.Y.)|November 18, 2010
From alpaca to zebrafish: hammerhead ribozymes wherever you lookCarsten Seehafer, Anne Kalweit, Gerhard Steger, et al.
The Journal of Physical Chemistry. B|December 20, 2014
Optical behavior of substituted 4-(2'-hydroxyphenyl)imidazolesArtur Jeżewski, Tommy Hammann, Piotr J Cywiński, et al.
Clinical Pharmacology in Drug Development|October 26, 2022
Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT-1014-6470, a Novel Oral Complement Factor 5a Receptor 1 AntagonistAnya Hammann-Hänni, Priska Kaufmann, Gernot Klein, et al.
Pageof 53

Showing results (141-150 of 526) with videos related to

Sort By:
Pageof 53
Clinical Pharmacology and Therapeutics|March 12, 2010
Prediction of adverse drug reactions using decision tree modelingF Hammann, H Gutmann, N Vogt, et al.
Virchows Archiv. A, Pathological Anatomy and Histopathology|January 1, 1991
Growth characteristics and metastatic potential of seven intestinal carcinoma lines serially passaged in syngeneic ratsM S Martin, F Martin, M F Michel, et al.
European Journal of Radiology|May 3, 2014
Volumetric quantification of the effect of aging and hormone replacement therapy on breast composition from digital mammogramsJ S Hammann-Kloss, U Bick, E Fallenberg, et al.
Genome Biology|August 23, 2001
Gene trapping identifies transiently induced survival genes during programmed cell deathF Wempe, J Y Yang, J Hammann, et al.
RNA (New York, N.Y.)|March 29, 2012
The ubiquitous hammerhead ribozymeChristian Hammann, Andrej Luptak, Jonathan Perreault, et al.
The Journal of Biological Chemistry|March 13, 1999
Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugsO Micheau, E Solary, A Hammann, et al.
Fortschritte Der Medizin|April 28, 1977
[The rectal carcinoma. Characteristics of the tumor and its position within the framework of colonic neoplasms]H J Hammann, M Eckert, H D Fux, et al.
RNA (New York, N.Y.)|November 18, 2010
From alpaca to zebrafish: hammerhead ribozymes wherever you lookCarsten Seehafer, Anne Kalweit, Gerhard Steger, et al.
The Journal of Physical Chemistry. B|December 20, 2014
Optical behavior of substituted 4-(2'-hydroxyphenyl)imidazolesArtur Jeżewski, Tommy Hammann, Piotr J Cywiński, et al.
Clinical Pharmacology in Drug Development|October 26, 2022
Effect of Severe Renal Impairment on Pharmacokinetics, Safety, and Tolerability of ACT-1014-6470, a Novel Oral Complement Factor 5a Receptor 1 AntagonistAnya Hammann-Hänni, Priska Kaufmann, Gernot Klein, et al.
Pageof 53